Hautamäki, Asta <br/><br/>
Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration.  [electronic resource] 

 -  Retina (Philadelphia, Pa.)  Oct 2013 
 - 1815-27 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1539-2864 
<br/><br/><label>Standard No.: </label>10.1097/IAE.0b013e318285cf92  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Alleles<br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Bevacizumab<br/>Complement C3--genetics<br/>Complement Factor H--genetics<br/>Exudates and Transudates<br/>Female<br/>Genotype<br/>Humans<br/>Interleukin-8--genetics<br/>Intravitreal Injections<br/>Male<br/>Middle Aged<br/>Pharmacogenetics<br/>Polymerase Chain Reaction<br/>Polymorphism, Single Nucleotide<br/>Promoter Regions, Genetic--genetics<br/>Prospective Studies<br/>Proteins--genetics<br/>Tomography, Optical Coherence<br/>Treatment Outcome<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors<br/>Visual Acuity--physiology<br/>Wet Macular Degeneration--diagnosis